Program
Voriconazole
Also written as “voriconazole”, “voriconazole (Vfend)” and “oral voriconazole”.
Its studies are mostly in Aspergillosis · Mycoses · Invasive Fungal Infections · Candidemia · Candidiasis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 200 open or running | phase 4since Aug 31, 2005 | Aug 25, 2005 | none ahead |
| Yung Shin Pharm. Ind. | 20 open or running | phase 4since Sep 21, 2016 | Sep 21, 2016 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 1since Dec 13, 2015 | Dec 13, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Aug 25, 2005.
- Oct 19, 2007Phase 4 study in CandidemiaPfizer · NCT00548262 · 54 enrolled · Brazil, Chile, Colombia and more
- Nov 9, 2007Phase 2 study in PharmacokineticsPfizer · NCT00556998 · 26 enrolled · United States
- Feb 8, 2008Phase 4 study in AspergillosisPfizer · NCT00620074 · 6 enrolled · United States
- Mar 27, 2008Phase 4 study in CandidiasisPfizer · NCT00647907 · 7 enrolled · Taiwan
- May 29, 2008Phase 3 study in Candidiasis, InvasivePfizer · NCT00689338 · 216 enrolled · Austria, Belgium, Canada and more
- Aug 20, 2008Phase 2 study in CandidiasisPfizer · NCT00739934 · 40 enrolled · United States
- Feb 3, 2009Phase 3 study in Invasive AspergillosisPfizer · NCT00836875 · 31 enrolled · United States, Canada, Czechia and more
- Mar 2, 2009Phase 1 study in Healthy VolunteersPfizer · NCT00855101 · 35 enrolled · Belgium
- Jul 13, 2009Phase 4 study in AspergillosisPfizer · NCT00940017 · 24 enrolled · United States
- Mar 10, 2010Phase 3 study in CandidiasisPfizer · NCT01092832 · 23 enrolled · China, Czech Republic, Hong Kong and more
- Jun 27, 2011Phase 2 study in AspergillosisPfizer · NCT01383993 · 21 enrolled · Japan
- Dec 13, 2015Chong Kun Dang Pharmaceutical's first study: phase 1 study in AspergillosisNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT02631954 · 24 enrolled · Korea, Republic of
- Sep 21, 2016Yung Shin Pharm. Ind.'s first study: phase 4 study in MycosesNew to Yung Shin Pharm. Ind.Yung Shin Pharm. Ind. · NCT02912156 · 29 enrolled
- Sep 11, 2020Phase 4 study in Antimycotic for Systematic UseYung Shin Pharm. Ind. · NCT04552353 · 14 enrolled · Taiwan
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04552353Antimycotic for Systematic Use · Taiwan | 4 | Completed | Yung Shin Pharm. Ind. | Jun 21, 2020 | 14 |
| NCT02912156Mycoses | 4 | Completed | Yung Shin Pharm. Ind. | Jul 2016 | 29 |
| NCT02631954Aspergillosis · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Oct 2015 | 24 |
| NCT01383993Aspergillosis · Japan | 2 | Completed | Pfizer | May 2013 | 21 |
| NCT01092832Candidiasis · China, Czech Republic, Hong Kong and more | 3 | Terminated | Pfizer | May 2013 | 23 |
| NCT00940017Aspergillosis · United States | 4 | Completed | Pfizer | Oct 2008 | 24 |
| NCT00855101Healthy Volunteers · Belgium | 1 | Completed | Pfizer | Jul 2009 | 35 |
| NCT00836875Invasive Aspergillosis · United States, Canada, Czechia and more | 3 | Terminated | Pfizer | May 2013 | 31 |
| NCT00739934Candidiasis · United States | 2 | Completed | Pfizer | Oct 2009 | 40 |
| NCT00689338Candidiasis, Invasive · Austria, Belgium, Canada and more | 3 | Completed | Pfizer | May 2010 | 216 |
| NCT00647907Candidiasis · Taiwan | 4 | Completed | Pfizer | 7 | |
| NCT00620074Aspergillosis · United States | 4 | Terminated | Pfizer | Feb 2009 | 6 |
| NCT00556998Pharmacokinetics · United States | 2 | Completed | Pfizer | Dec 2009 | 26 |
| NCT00548262Candidemia · Brazil, Chile, Colombia and more | 4 | Completed | Pfizer | Oct 2009 | 54 |
| NCT00300677Mycoses · United States | 4 | Completed | Pfizer | Aug 2008 | 12 |
| NCT00289991Antifungal Prophylaxis of Invasive Fungal Infections · Canada, Czech Republic, Egypt and more | 3 | Completed | Pfizer | Feb 2009 | 489 |
| NCT00288197Invasive Fungal Infections · China | 4 | Completed | Pfizer | Jun 2007 | 77 |
| NCT00174473Neutropenia | 2 | Completed | Pfizer | 49 | |
| NCT00159822Aspergillosis · France | 3 | Completed | Pfizer | Dec 2008 | 48 |
| NCT00150345Neutropenia · Germany | 3 | Completed | Pfizer | Apr 2009 | 147 |
| NCT00150319Renal Insufficiency · United States | 2 | Terminated | Pfizer | Oct 2005 | 1 |
| NCT00143312Invasive Fungal Infections · Belgium, France, Germany and more | 4 | Completed | Pfizer | Apr 2008 | 45 |
| NCT00136968Mycoses | 1 | Completed | Pfizer | 12 |
How it is read
Names in the registry
- “Voriconazole”, 13 entries
- “voriconazole”, 7 entries
- “voriconazole (Vfend)”, 3 entries
- “oral voriconazole”, 1 entry
- “Vaway”, 1 entry
Conditions, from the studies’ own filings
- Aspergillosis, 7 studies
- Mycoses, 3 studies
- Invasive Fungal Infections, 3 studies
- Candidemia, 3 studies
- Candidiasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.